Systemic reactogenicity events
AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).
1 finding from 1 review
Any adverse eventh
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed symptomatic COVID‐19b
1 finding from 1 review
Systemic reactogenicity events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe or critical COVID‐19
1 finding from 1 review
All‐cause mortalityf
It is very uncertain whether gam‐COVID‐VAC – Sputnik V changes all‐cause mortalityf compared with placebo (very low certainty).
1 finding from 1 review
Systemic reactogenicity events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse eventsf
Gam‐COVID‐VAC – Sputnik V showed no clear difference in serious adverse eventsf compared with placebo (low certainty).
1 finding from 1 review
Local reactogenicity events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed symptomatic COVID‐19b
1 finding from 1 review
Severe or critical COVID‐19
1 finding from 1 review
All‐cause mortalityh
CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
1 finding from 1 review
Any adverse eventi
1 finding from 1 review
Systemic reactogenicity events
CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).
1 finding from 1 review
Any adverse evento
CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).
1 finding from 1 review
Serious adverse eventsr
CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).
1 finding from 1 review
Local reactogenicity events
CoronaVac – Sinovac leads to higher local reactogenicity eventsj compared with placebo (high certainty).
1 finding from 1 review